prednisolone has been researched along with Cancer of Prostate in 98 studies
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We have experienced a patient with tumor fever from hormone-refractory prostate cancer (HRPC) who was treated successfully using docetaxel plus prednisolone therapy." | 7.73 | [A case of hormone-refractory prostate cancer (HRPC) with tumor fever responding to docetaxel plus prednisolone therapy]. ( Azuma, K; Hashine, K; Miura, N; Numata, K; Sumiyoshi, Y, 2006) |
| "Flutamide is an antiandrogen and frequently used for the treatment of prostatic cancer." | 6.42 | [Toxic hepatitis and liver failure under therapy with flutamide]. ( Haupt, R; Lübbert, C; Ruf, BR; Wiese, M, 2004) |
| "The antiemetic effect of prednisolone on nausea/vomiting was investigated in 67 patients with advanced prostatic cancer and a performance status of < or = 2." | 5.08 | Antiemetic efficacy of prednisolone: a placebo-controlled trial in patients with advanced prostatic cancer treated with estramustine phosphate. ( Bosson, S; Eriksson, T; Henricsson, A; Josefsson, K; Madsen, M; Palmqvist, E; Schelin, S, 1998) |
| "We have experienced a patient with tumor fever from hormone-refractory prostate cancer (HRPC) who was treated successfully using docetaxel plus prednisolone therapy." | 3.73 | [A case of hormone-refractory prostate cancer (HRPC) with tumor fever responding to docetaxel plus prednisolone therapy]. ( Azuma, K; Hashine, K; Miura, N; Numata, K; Sumiyoshi, Y, 2006) |
| "Among men with high-risk non-metastatic prostate cancer, combination therapy is associated with significantly higher rates of metastasis-free survival compared with ADT alone." | 2.82 | Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. ( Alzoueb, M; Amos, CL; Atako, N; Attard, G; Birtle, A; Bowen, J; Brawley, C; Brown, LC; Buckner, M; Chowdhury, S; Clarke, NW; Cook, A; Cross, W; Das, P; de Bono, JS; Dearnaley, DP; Gale, J; Gilbert, D; Gillessen, S; Gilson, C; Gray, E; James, ND; Jones, RJ; Langley, RE; Lydon, A; Malik, Z; Mason, MD; Matheson, D; Millman, R; Murphy, L; O'Sullivan, JM; Parikh, O; Parker, CC; Parmar, MKB; Pedley, I; Pugh, C; Robinson, A; Rush, H; Russell, JM; Srihari, N; Sydes, MR; Syndikus, I; Tanguay, J; Thalmann, G; Thomas, C; Wagstaff, J; Wylie, J; Zarkar, A, 2022) |
| "Prednisolone monotherapy has been the standard systemic treatment in many patients with androgen- independent prostate cancer and should today be compared to treatment with Taxotere plus prednisolone." | 2.73 | A randomized phase II trial comparing weekly taxotere plus prednisolone versus prednisolone alone in androgen-independent prostate cancer. ( Fosså, SD, 2008) |
| "Hormone-refractory prostate cancer (HRPC) is a rapidly progressive disease which produces considerable morbidity and involves mostly men over 70, often comorbid and with poor tolerance to chemotherapy." | 2.73 | Oral vinorelbine as first line chemotherapy in unfit elderly patients with hormone-refractory prostate cancer. ( Adamo, V; Buda, C; Caristi, N; Iorfida, M; Lupo, G; Maisano, R; Scimone, A; Scisca, C, 2008) |
| "Abiraterone acetate is an orally active acetate salt of the steroidal compound abiraterone with antiandrogen activity." | 2.48 | Abiraterone acetate in castration-resistant prostate cancer. ( Cortesi, E; Gazzaniga, P; Iacovelli, R; Palazzo, A; Procopio, G, 2012) |
| "Abiraterone acetate has recently demonstrated a significant improvement in survival when compared to placebo in patients with docetaxel-treated mCRPC." | 2.47 | Role of second-line systemic treatment post-docetaxel in metastatic castrate resistant prostate cancer- current strategies and future directions. ( Alhasso, A; Ansari, A; Ansari, J; Glaholm, J; Hussain, SA; Mahmood, R, 2011) |
| "Advanced prostate cancer is typically sensitive to androgen-deprivation therapy, but invariably progresses to the castration-resistant state." | 2.47 | Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting. ( de Bono, JS; Massard, C; Michels, RM; Sartor, O, 2011) |
| "Treatment of hormone-refractory prostate cancer is palliative, and surgery and radiotherapy are used for the relief of lower urinary tract symptoms and localized painful bony metastases." | 2.43 | The changing pattern of management for hormone-refractory, metastatic prostate cancer. ( Bloomfield, D; James, ND; Luscombe, C, 2006) |
| "Flutamide is an antiandrogen and frequently used for the treatment of prostatic cancer." | 2.42 | [Toxic hepatitis and liver failure under therapy with flutamide]. ( Haupt, R; Lübbert, C; Ruf, BR; Wiese, M, 2004) |
| "Although prostate cancer is a very common form of malignancy in men, the clinical significance of androgen deprivation therapy (ADT) with abiraterone acetate versus the nonsteroidal antiandrogen bicalutamide has not yet been verified in patients with high-risk metastatic hormone-sensitive prostate cancer (mHSPC)." | 1.72 | Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high-risk metastatic hormone-sensitive prostate cancer. ( Egawa, S; Enei, Y; Fukuokaya, W; Hata, K; Iwamoto, Y; Kimura, T; Matsukawa, A; Miki, J; Miyajima, K; Mori, K; Obayashi, K; Onuma, H; Otsuka, T; Sakanaka, K; Sano, T; Shimomura, T; Suzuki, H; Tsuzuki, S; Yanagisawa, T, 2022) |
| "The 2022 Swedish prostate cancer guidelines include several new recommendations and some that differ from the European guidelines." | 1.72 | The Swedish national guidelines on prostate cancer, part 1: early detection, diagnostics, staging, patient support and primary management of non-metastatic disease. ( Bratt, O; Carlsson, S; Fransson, P; Kindblom, J; Stranne, J; Thellenberg Karlsson, C, 2022) |
| "Metastatic prostate cancer, Hormone resistant prostate cancer, Weekly docetaxel." | 1.72 | Comparison of Weekly Low Dose Docetaxel with the Standard Protocol in Hormone-resistant Metastatic Prostate Cancer. ( Celenkoglu, G; Sayin, M, 2022) |
| "Prostate cancer is a commonly diagnosed and treated malignancy, although it rarely presents with cutaneous metastases." | 1.40 | Cutaneous metastasis of prostate carcinoma treated with radiotherapy: a case presentation. ( Chin, M; De Souza, P; Mak, G; Nahar, N, 2014) |
| "Abiraterone was well tolerated." | 1.39 | Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). ( Albiges, L; Attard, G; Bianchini, D; De Bono, JS; Fizazi, K; Ileana, E; Loriot, Y; Massard, C; Patrikidou, A; Pezaro, C; Sandhu, S, 2013) |
| "Treatment with cabazitaxel plus prednisone has improved overall survival of 2." | 1.38 | [Cabazitaxel after docetaxel: a new option in metastatic castration-resistant prostate cancer]. ( Joly, F; Lheureux, S, 2012) |
| "We describe interstitial pneumonitis induced by bicalutamide prescribed to treat prostate cancer." | 1.37 | Interstitial pneumonitis induced by bicalutamide given for prostate cancer. ( Masago, T; Motoda, K; Nemoto, R; Watanabe, T, 2011) |
| "The objective of this study was to evaluate the efficacy and toxicity of docetaxel in combination with prednisolone in Japanese patients with hormone refractory prostate cancer." | 1.36 | Docetaxel in combination with prednisolone for hormone refractory prostate cancer. ( Ide, H; Kikuchi, E; Kono, H; Miyajima, A; Nagata, H; Nakagawa, K; Nakashima, J; Ohigashi, T; Oya, M, 2010) |
| "Patients with recurrent prostate cancer may be treated with androgen deprivation strategies; however, most patients will develop androgen-independent prostate cancer." | 1.33 | Docetaxel-based regimens, the standard of care for metastatic androgen-insensitive prostate cancer. ( Arlen, PM; Gulley, JL, 2005) |
| "A 88-year-old man with prostate cancer was receiving non-steroidal anti-androgen therapy (flutamide, 375 mg/day)." | 1.32 | Interstitial pneumonitis related to flutamide monotherapy for prostate cancer. ( Fujimoto, N; Matsumoto, T; Nomura, M; Sato, H, 2004) |
| "Biopsy specimen revealed malignant lymphoma." | 1.28 | [Triple malignancy including bladder carcinoma, prostate carcinoma and malignant lymphoma: a case report]. ( Kobayashi, Y; Kuyama, J; Matsuda, M; Miyagawa, M; Ohnishi, S; Oritani, K; Tada, Y; Yasunaga, Y; Yoshioka, T, 1989) |
| "Estramustine has been shown previously to be an effective drug in the treatment of metastatic prostatic cancer, demonstrating significant objective and subjective responses in long-term non-randomized trials and in other randomized trials." | 1.26 | The use of estramustine and prednimustine versus prednimustine alone in advanced metastatic prostatic cancer patients who have received prior irradiation. ( Chu, TM; Gaeta, JF; Gibbons, RP; Johnson, DE; Loening, SA; Murphy, GP; Prout, GR; Saroff, J; Schmidt, JD; Scott, WW; Slack, N; Soloway, MS; Wajsman, Z, 1979) |
| "Estramustine is a combination of estradiol and nitrogen mustard, and alone has shown objective responses in advanced prostatic cancer." | 1.26 | Combined therapy of advanced prostatic carcinoma with estramustine and prednimustine. ( Catane, R; Kaufman, J; Mittelman, A; Murphy, GP, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (12.24) | 18.7374 |
| 1990's | 7 (7.14) | 18.2507 |
| 2000's | 27 (27.55) | 29.6817 |
| 2010's | 41 (41.84) | 24.3611 |
| 2020's | 11 (11.22) | 2.80 |
| Authors | Studies |
|---|---|
| Kularatne, SA | 1 |
| Venkatesh, C | 1 |
| Santhapuram, HK | 1 |
| Wang, K | 1 |
| Vaitilingam, B | 1 |
| Henne, WA | 1 |
| Low, PS | 1 |
| Yanagisawa, T | 1 |
| Kimura, T | 1 |
| Mori, K | 1 |
| Suzuki, H | 2 |
| Sano, T | 1 |
| Otsuka, T | 1 |
| Iwamoto, Y | 1 |
| Fukuokaya, W | 1 |
| Miyajima, K | 1 |
| Enei, Y | 1 |
| Sakanaka, K | 1 |
| Matsukawa, A | 1 |
| Onuma, H | 1 |
| Obayashi, K | 1 |
| Tsuzuki, S | 1 |
| Hata, K | 1 |
| Shimomura, T | 1 |
| Miki, J | 1 |
| Egawa, S | 1 |
| Attard, G | 7 |
| Murphy, L | 2 |
| Clarke, NW | 6 |
| Cross, W | 3 |
| Jones, RJ | 6 |
| Parker, CC | 4 |
| Gillessen, S | 5 |
| Cook, A | 3 |
| Brawley, C | 3 |
| Amos, CL | 3 |
| Atako, N | 1 |
| Pugh, C | 3 |
| Buckner, M | 1 |
| Chowdhury, S | 4 |
| Malik, Z | 3 |
| Russell, JM | 6 |
| Gilson, C | 4 |
| Rush, H | 3 |
| Bowen, J | 2 |
| Lydon, A | 1 |
| Pedley, I | 2 |
| O'Sullivan, JM | 3 |
| Birtle, A | 3 |
| Gale, J | 4 |
| Srihari, N | 2 |
| Thomas, C | 3 |
| Tanguay, J | 2 |
| Wagstaff, J | 4 |
| Das, P | 3 |
| Gray, E | 3 |
| Alzoueb, M | 1 |
| Parikh, O | 4 |
| Robinson, A | 3 |
| Syndikus, I | 2 |
| Wylie, J | 4 |
| Zarkar, A | 3 |
| Thalmann, G | 1 |
| de Bono, JS | 6 |
| Dearnaley, DP | 5 |
| Mason, MD | 5 |
| Gilbert, D | 3 |
| Langley, RE | 3 |
| Millman, R | 5 |
| Matheson, D | 4 |
| Sydes, MR | 6 |
| Brown, LC | 2 |
| Parmar, MKB | 6 |
| James, ND | 7 |
| Grünwald, V | 1 |
| Ohlmann, CH | 1 |
| Hadaschik, B | 1 |
| Ali, A | 1 |
| Hoyle, AP | 1 |
| Brawley, CD | 2 |
| Cross, WR | 2 |
| Diaz-Montana, C | 2 |
| Malik, ZI | 2 |
| Matheson, DJ | 1 |
| Berthold, DR | 2 |
| Buckner, ML | 1 |
| Ritchie, AWS | 2 |
| Birtle, AJ | 2 |
| Brock, SJ | 1 |
| Ford, D | 1 |
| Grant, W | 2 |
| Gray, EK | 1 |
| Hoskin, P | 1 |
| Khan, MM | 1 |
| Manetta, C | 1 |
| McPhail, NJ | 1 |
| Perna, C | 1 |
| Pezaro, CJ | 1 |
| Protheroe, AS | 1 |
| Robinson, AJ | 1 |
| Rudman, SM | 1 |
| Sheehan, DJ | 1 |
| Srihari, NN | 2 |
| Tanguay, JS | 1 |
| Thomas, CW | 1 |
| Vengalil, S | 1 |
| Wylie, JP | 1 |
| Clarke, CS | 1 |
| Hunter, RM | 1 |
| Gabrio, A | 1 |
| Ingleby, FC | 1 |
| Rush, HL | 1 |
| Parker, C | 2 |
| Lester, JF | 2 |
| Bratt, O | 1 |
| Carlsson, S | 1 |
| Fransson, P | 1 |
| Thellenberg Karlsson, C | 1 |
| Stranne, J | 1 |
| Kindblom, J | 1 |
| Sayin, M | 1 |
| Celenkoglu, G | 1 |
| Uemura, H | 2 |
| Matsumoto, R | 1 |
| Mizokami, A | 3 |
| Miyake, H | 2 |
| Matsuyama, H | 1 |
| Nakamura, K | 1 |
| Saito, K | 1 |
| Kawakita, M | 1 |
| Takeshita, H | 1 |
| Koroki, Y | 1 |
| Ono, S | 1 |
| Murota, M | 1 |
| Ito, M | 1 |
| Kamoto, T | 1 |
| Fujimoto, K | 1 |
| Sachdeva, A | 1 |
| Jones, C | 1 |
| Hoyle, A | 1 |
| Abdel-Aty, H | 1 |
| Murphy, C | 1 |
| Parkar, N | 1 |
| Pezaro, C | 3 |
| Saxby, H | 1 |
| Alzouebi, M | 1 |
| Montazeri, AH | 1 |
| Cathomas, R | 1 |
| Brown, MD | 1 |
| Jain, Y | 1 |
| George, DJ | 1 |
| Kimura, G | 1 |
| Fujii, Y | 1 |
| Hinotsu, S | 1 |
| Izumi, K | 1 |
| Ly, LK | 1 |
| Rowles, JL | 1 |
| Paul, HM | 1 |
| Alves, JMP | 1 |
| Yemm, C | 1 |
| Wolf, PM | 1 |
| Devendran, S | 1 |
| Hudson, ME | 1 |
| Morris, DJ | 1 |
| Erdman, JW | 1 |
| Ridlon, JM | 1 |
| Yasukawa, H | 1 |
| Ikehata, Y | 1 |
| Tsuboi, Y | 1 |
| Nishiyama, N | 2 |
| Watanabe, A | 1 |
| Fujiuchi, Y | 1 |
| Kitamura, H | 1 |
| Fizazi, K | 3 |
| Tran, N | 1 |
| Fein, L | 1 |
| Matsubara, N | 1 |
| Rodriguez-Antolin, A | 1 |
| Alekseev, BY | 1 |
| Özgüroğlu, M | 1 |
| Ye, D | 1 |
| Feyerabend, S | 1 |
| Protheroe, A | 2 |
| De Porre, P | 1 |
| Kheoh, T | 1 |
| Park, YC | 1 |
| Todd, MB | 1 |
| Chi, KN | 1 |
| Spears, MR | 2 |
| Adab, F | 1 |
| Aung, S | 1 |
| Brock, S | 1 |
| Chakraborti, P | 1 |
| Ferguson, C | 1 |
| Hingorani, M | 1 |
| Hoskin, PJ | 1 |
| McKinna, F | 1 |
| McPhail, N | 1 |
| Money-Kyrle, J | 1 |
| O'Sullivan, J | 1 |
| Struss, WJ | 1 |
| Black, PC | 1 |
| Hahn, AW | 1 |
| Hale, P | 1 |
| Rathi, N | 1 |
| Agarwal, N | 1 |
| Rulach, RJ | 1 |
| McKay, S | 1 |
| Neilson, S | 1 |
| White, L | 1 |
| Wallace, J | 1 |
| Carruthers, R | 1 |
| Lamb, C | 1 |
| Cascales, A | 1 |
| Marashi, H | 1 |
| Glen, H | 1 |
| Venugopal, B | 1 |
| Sadoyze, A | 1 |
| Sidek, N | 1 |
| Alhasso, A | 2 |
| Dodds, D | 1 |
| Laskey, J | 1 |
| MacLeod, N | 1 |
| Vale, CL | 1 |
| Fisher, DJ | 1 |
| White, IR | 1 |
| Carpenter, JR | 1 |
| Burdett, S | 1 |
| Gravis, G | 1 |
| Rydzewska, LH | 1 |
| Sweeney, CJ | 1 |
| Tierney, JF | 1 |
| Spratt, DE | 1 |
| Loriot, Y | 1 |
| Bianchini, D | 1 |
| Ileana, E | 1 |
| Sandhu, S | 1 |
| Patrikidou, A | 1 |
| Albiges, L | 1 |
| Massard, C | 2 |
| End, D | 1 |
| Molina, A | 1 |
| Todd, M | 1 |
| Meyers, ML | 1 |
| Kusukawa, N | 2 |
| Ishida, H | 1 |
| Tanase, K | 1 |
| Ito, H | 2 |
| Aoki, Y | 1 |
| Ooyama, N | 1 |
| Akino, H | 2 |
| Yokoyama, O | 2 |
| Inamura, S | 1 |
| Taga, M | 1 |
| Tsuchiyama, K | 1 |
| Oyama, N | 1 |
| Lee, JL | 1 |
| Ahn, JH | 1 |
| Choi, MK | 1 |
| Kim, Y | 1 |
| Hong, SW | 1 |
| Lee, KH | 1 |
| Jeong, IG | 1 |
| Song, C | 1 |
| Hong, BS | 1 |
| Hong, JH | 1 |
| Ahn, H | 1 |
| Mak, G | 1 |
| Chin, M | 1 |
| Nahar, N | 1 |
| De Souza, P | 1 |
| Moriceau, G | 1 |
| Guillot, A | 1 |
| Pacaut, C | 1 |
| Méry, B | 1 |
| Falk, AT | 1 |
| Trone, JC | 1 |
| Collard, O | 1 |
| De Laroche, G | 1 |
| Fournel, P | 1 |
| Merrouche, Y | 1 |
| Magné, N | 1 |
| Ureshino, H | 1 |
| Miyahara, M | 1 |
| Fosså, SD | 4 |
| Caristi, N | 1 |
| Maisano, R | 1 |
| Iorfida, M | 1 |
| Scimone, A | 1 |
| Lupo, G | 1 |
| Buda, C | 1 |
| Scisca, C | 1 |
| Adamo, V | 1 |
| Naito, M | 1 |
| Itoh, K | 1 |
| Komatsu, N | 1 |
| Yamashita, Y | 1 |
| Shirakusa, T | 1 |
| Yamada, A | 1 |
| Moriya, F | 1 |
| Ayatuka, H | 1 |
| Mohamed, ER | 1 |
| Matsuoka, K | 2 |
| Noguchi, M | 1 |
| Horti, J | 1 |
| Widmark, A | 1 |
| Stenzl, A | 1 |
| Federico, MH | 1 |
| Abratt, RP | 1 |
| Sanders, N | 1 |
| Pover, GM | 1 |
| Bodrogi, I | 1 |
| Ide, H | 1 |
| Kikuchi, E | 1 |
| Kono, H | 1 |
| Nagata, H | 1 |
| Miyajima, A | 1 |
| Nakagawa, K | 1 |
| Ohigashi, T | 1 |
| Nakashima, J | 1 |
| Oya, M | 1 |
| Kaprin, AD | 1 |
| Gafanov, RA | 1 |
| Al'bitskiĭ, IA | 1 |
| Fastovets, SV | 1 |
| Chin, K | 1 |
| Fujimura, M | 1 |
| Sekit, N | 1 |
| Mikami, K | 1 |
| Kamijima, S | 1 |
| Ichikawa, T | 1 |
| Miura, N | 3 |
| Numata, K | 3 |
| Kusuhara, Y | 1 |
| Shirato, A | 1 |
| Hashine, K | 4 |
| Sumiyoshi, Y | 4 |
| Maehana, T | 1 |
| Mizuno, T | 1 |
| Muto, M | 1 |
| Yanase, M | 1 |
| Ladoire, S | 1 |
| Eymard, JC | 1 |
| Zanetta, S | 1 |
| Mignot, G | 1 |
| Martin, E | 1 |
| Kermarrec, I | 1 |
| Mourey, E | 1 |
| Michel, F | 1 |
| Cormier, L | 1 |
| Ghiringhelli, F | 1 |
| Kinouchi, T | 1 |
| Kinoshita, T | 1 |
| Kobayashi, M | 2 |
| Ueda, T | 1 |
| Inoue, H | 1 |
| Takada, T | 1 |
| Hara, T | 1 |
| Yamaguchi, T | 1 |
| Kamiya, K | 1 |
| Izumi, N | 1 |
| Hisanaga, T | 1 |
| Higashi, K | 1 |
| Shima, Y | 1 |
| Hirayama, Y | 1 |
| Ito, Y | 1 |
| Kanamaru, T | 1 |
| Sonoda, T | 1 |
| Aoyama, M | 1 |
| Nakamura, N | 1 |
| Kawamura, M | 1 |
| Ansari, J | 1 |
| Hussain, SA | 1 |
| Mahmood, R | 1 |
| Ansari, A | 1 |
| Glaholm, J | 1 |
| Masago, T | 1 |
| Watanabe, T | 2 |
| Nemoto, R | 1 |
| Motoda, K | 1 |
| Yanagi, M | 1 |
| Nishimura, T | 1 |
| Kurita, S | 1 |
| Lee, C | 1 |
| Kondo, Y | 1 |
| Yamazaki, K | 1 |
| Sartor, O | 1 |
| Michels, RM | 1 |
| Al-Mohizea, AM | 1 |
| Al-Omar, MA | 1 |
| Abdalla, MM | 1 |
| Amr, AG | 1 |
| Ohmori, S | 1 |
| Yaguchi, T | 1 |
| Nakamura, M | 1 |
| Iacovelli, R | 1 |
| Palazzo, A | 1 |
| Procopio, G | 1 |
| Gazzaniga, P | 1 |
| Cortesi, E | 1 |
| Jones, M | 1 |
| Kobylecki, C | 1 |
| Marshall, AG | 1 |
| Silverdale, MA | 1 |
| Talbot, PR | 1 |
| Muramaki, M | 1 |
| Fujisawa, M | 1 |
| Nishimura, K | 1 |
| Nonomura, N | 1 |
| Kanayama, HO | 1 |
| Ozono, S | 1 |
| Miura, T | 1 |
| Miki, T | 1 |
| Kakehi, Y | 1 |
| Arai, Y | 1 |
| Ogawa, O | 1 |
| Fujita, R | 1 |
| Nonomura, K | 1 |
| Hoshi, S | 2 |
| Akaza, H | 2 |
| Richards, J | 1 |
| Lim, AC | 1 |
| Hay, CW | 1 |
| Taylor, AE | 1 |
| Wingate, A | 1 |
| Nowakowska, K | 1 |
| Carreira, S | 1 |
| Goodall, J | 1 |
| Arlt, W | 1 |
| McEwan, IJ | 1 |
| Perry, CJ | 1 |
| Sundar, S | 1 |
| Lheureux, S | 1 |
| Joly, F | 1 |
| Dyer, M | 1 |
| Rinaldi, F | 1 |
| George, E | 1 |
| Adler, AI | 1 |
| Rezvani, H | 1 |
| Haghighi, S | 1 |
| Ghadyani, M | 1 |
| Attarian, H | 1 |
| Lübbert, C | 1 |
| Wiese, M | 1 |
| Haupt, R | 1 |
| Ruf, BR | 1 |
| Sekine, Y | 1 |
| Kubota, Y | 2 |
| Kurihara, J | 1 |
| Sheen, WC | 1 |
| Chen, JS | 1 |
| Wang, HM | 1 |
| Yang, TS | 1 |
| Liaw, CC | 1 |
| Lin, YC | 1 |
| Nomura, M | 1 |
| Sato, H | 1 |
| Fujimoto, N | 1 |
| Matsumoto, T | 1 |
| Rexer, H | 1 |
| Famularo, G | 1 |
| Minisola, G | 1 |
| Grieco, A | 1 |
| Miele, L | 1 |
| Emberton, M | 1 |
| Miyahara, T | 1 |
| Oyabul, Y | 1 |
| Hayashi, T | 1 |
| Shimizu, S | 1 |
| Tanaka, H | 2 |
| Sternberg, CN | 1 |
| Arlen, PM | 1 |
| Gulley, JL | 1 |
| Nakanishi, S | 1 |
| Hatayama, T | 1 |
| Azuma, K | 2 |
| Bloomfield, D | 1 |
| Luscombe, C | 1 |
| Collins, R | 1 |
| Trowman, R | 1 |
| Norman, G | 1 |
| Light, K | 1 |
| Fenwick, E | 1 |
| Palmer, S | 1 |
| Riemsma, R | 1 |
| Jacobsen, AB | 1 |
| Ginman, C | 1 |
| Jacobsen, IN | 1 |
| Overn, S | 1 |
| Iversen, JR | 1 |
| Urnes, T | 2 |
| Dahl, AA | 1 |
| Veenstra, M | 1 |
| Sandstad, B | 1 |
| Bracarda, S | 1 |
| Kibble, A | 1 |
| Naito, S | 1 |
| Tsukamoto, T | 1 |
| Koga, H | 1 |
| Harabayashi, T | 1 |
| Andersson, L | 1 |
| Edsmyr, F | 1 |
| Esposti, PL | 1 |
| Hedlund, PO | 1 |
| Rönström, L | 1 |
| Beckley, S | 1 |
| Wajsman, LZ | 1 |
| Slack, NH | 1 |
| Murphy, GP | 5 |
| Morozumi, M | 1 |
| Takasu, H | 1 |
| Okada, M | 1 |
| Suwa, Y | 1 |
| Noguchi, S | 1 |
| Sakuramoto, T | 1 |
| Shuin, T | 1 |
| Kinoshita, Y | 1 |
| Hosaka, M | 1 |
| Maeda, N | 1 |
| Nishizaki, S | 1 |
| Furubayashi, T | 1 |
| Datta, SN | 1 |
| Thomas, K | 1 |
| Matthews, PN | 1 |
| Enomoto, Y | 1 |
| Fukuhara, H | 1 |
| Kurimoto, S | 1 |
| Sugimoto, M | 1 |
| Kimura, A | 1 |
| Hosaka, Y | 1 |
| Kitamura, T | 1 |
| Schelin, S | 1 |
| Palmqvist, E | 1 |
| Madsen, M | 1 |
| Bosson, S | 1 |
| Eriksson, T | 1 |
| Henricsson, A | 1 |
| Josefsson, K | 1 |
| Kobayashi, T | 1 |
| Jo, Y | 1 |
| Ikegami, M | 1 |
| Furukawa, Y | 1 |
| Morioka, M | 1 |
| Kinugawa, K | 1 |
| Ohta, S | 1 |
| Culine, S | 1 |
| Droz, JP | 1 |
| Gibbons, RP | 1 |
| Johnson, DE | 1 |
| Prout, GR | 1 |
| Schmidt, JD | 1 |
| Soloway, MS | 1 |
| Loening, SA | 1 |
| Chu, TM | 1 |
| Gaeta, JF | 1 |
| Saroff, J | 1 |
| Wajsman, Z | 1 |
| Slack, N | 1 |
| Scott, WW | 1 |
| Catane, R | 3 |
| Kaufman, JH | 1 |
| Madajewicz, S | 1 |
| Mittelman, A | 2 |
| Kaufman, J | 1 |
| Saha, PK | 1 |
| Hyakutake, H | 1 |
| Nomata, K | 1 |
| Yushita, Y | 1 |
| Kanetake, H | 1 |
| Saito, Y | 1 |
| Kaalhus, O | 1 |
| Kobayashi, Y | 1 |
| Yasunaga, Y | 1 |
| Yoshioka, T | 1 |
| Matsuda, M | 1 |
| Oritani, K | 1 |
| Kuyama, J | 1 |
| Ohnishi, S | 1 |
| Tada, Y | 1 |
| Miyagawa, M | 1 |
| Portnoĭ, AS | 1 |
| Jahnsen, JU | 1 |
| Karlsen, S | 1 |
| Ogreid, P | 1 |
| Haveland, H | 1 |
| Trovåg, A | 1 |
| Dreyer, CV | 1 |
| Winter, CC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial[NCT00268476] | Phase 2/Phase 3 | 11,992 participants (Actual) | Interventional | 2005-07-08 | Active, not recruiting | ||
| A Randomized Phase II Trial Comparing Biomarker Directed Therapy Versus Clinician's Choice of Enzalutamide or Docetaxel in Patients With Advanced Prostate Cancer Post Abiraterone[NCT04015622] | Phase 2 | 100 participants (Anticipated) | Interventional | 2020-10-07 | Recruiting | ||
| A Randomized, Double-blind, Comparative Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk, Metastatic Hormone-naive Prostate Cancer (mHNPC)[NCT01715285] | Phase 3 | 1,209 participants (Actual) | Interventional | 2013-02-12 | Completed | ||
| An Open-label, Phase I/IIa Dose Escalation and Expansion Study to Determine the Safety and Clinical Activity of an Immune Priming Cell Therapy (INKmune) in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)[NCT06056791] | Phase 1/Phase 2 | 30 participants (Anticipated) | Interventional | 2023-11-30 | Not yet recruiting | ||
| A Single-center, Phase II Neoadjuvant Study of Abiraterone Acetate in the Treatment of Intraductal Carcinoma of the Prostate[NCT04736108] | Phase 2 | 50 participants (Anticipated) | Interventional | 2021-05-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Overall survival was defined as the time from randomization to date of death from any cause. (NCT01715285)
Timeframe: Up to 66 months
| Intervention | months (Median) |
|---|---|
| Abiraterone Acetate+Prednisone+ADT | 53.32 |
| Placebo + ADT | 36.53 |
Radiographic PFS was defined as the time (in months) interval from randomization to the first date of radiographic progression or death. Radiographic progression included progression by bone scan (according to modified Prostate Cancer Working Group 2 [PCWG2] criteria), defined as at least 2 new lesions on bone scan and progression of soft tissue lesions by computed tomography (CT) or magnetic resonance imaging (MRI) (according to Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 criteria). As per the RECIST 1.1 guideline, progression requires a 20 percent (%) increase in the sum of diameters of all target lesions and a minimum absolute increase of 5 millimeter (mm) in the sum as compared to nadir sum of diameter. (NCT01715285)
Timeframe: Up to 44 months
| Intervention | Months (Median) |
|---|---|
| Abiraterone Acetate+Prednisone+ADT | 33.02 |
| Placebo + ADT | 14.78 |
Time to initiation of chemotherapy was defined as the time (in months) interval from the date of randomization to the date of initiation of cytotoxic chemotherapy for prostate cancer. (NCT01715285)
Timeframe: Up to 66 months
| Intervention | months (Median) |
|---|---|
| Abiraterone Acetate+Prednisone+ADT | NA |
| Placebo + ADT | 57.59 |
"Time to pain progression was defined as the time (in months) interval from randomization to the first date a participant experienced a greater than or equal to (>=) 30 percent (%) increase in Brief Pain Inventory-Short Form (BPI-SF) from baseline in the BPI-SF worst pain intensity (Item 3) observed at 2 consecutive evaluations (>=4) weeks apart. BPI-SF was an 11-item questionnaire, designed to assess severity and impact of pain on daily functions. Total score ranged from 0 to 10 with 0 representing no pain and 10 representing pain as bad as you can imagine." (NCT01715285)
Timeframe: Up to 66 months
| Intervention | Months (Median) |
|---|---|
| Abiraterone Acetate+Prednisone+ADT | 47.41 |
| Placebo + ADT | 16.62 |
Time to PSA progression was defined as the time (in months) interval from the date of randomization to the date of PSA progression, according to PCWG2 criteria. PCWG2 defines PSA progression as the date that a 25 percent (%) or greater increase and an absolute increase of 2 nanogram per milliliter (ng/mL) or more from the nadir is documented, which is confirmed by a second value obtained 3 or more weeks later. (NCT01715285)
Timeframe: Up to 66 months
| Intervention | Months (Median) |
|---|---|
| Abiraterone Acetate+Prednisone+ADT | 33.31 |
| Placebo + ADT | 7.43 |
Time to skeletal-related event was defined as the earliest of the following: clinical or pathological fracture, spinal cord compression, palliative radiation to bone, or surgery to bone. (NCT01715285)
Timeframe: Up to 66 months
| Intervention | months (Median) |
|---|---|
| Abiraterone Acetate+Prednisone+ADT | NA |
| Placebo + ADT | NA |
Time to subsequent therapy was defined as the time (in months) interval from the date of randomization to the date of initiation of subsequent therapy for prostate cancer. (NCT01715285)
Timeframe: Up to 66 months
| Intervention | Months (Median) |
|---|---|
| Abiraterone Acetate+Prednisone+ADT | 54.87 |
| Placebo + ADT | 21.22 |
17 reviews available for prednisolone and Cancer of Prostate
| Article | Year |
|---|---|
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chemotherapy, Adjuv | 2022 |
Novel androgen axis systemic therapies for metastatic hormone-sensitive prostate cancer.
Topics: Androgen Antagonists; Androgens; Androstenes; Antineoplastic Agents, Hormonal; Antineoplastic Combin | 2017 |
What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis.
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Disease P | 2018 |
[Case of malignant lymphoma of the prostate complicated with prostate adenocarcinoma].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic | 2009 |
[Scleroderma-like skin sclerosis induced by docetaxel chemotherapy for hormone refractory prostate cancer: a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; | 2010 |
[A case of primary malignant lymphoma of the prostate presenting as urinary retention].
Topics: Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Ag | 2010 |
Role of second-line systemic treatment post-docetaxel in metastatic castrate resistant prostate cancer- current strategies and future directions.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cl | 2011 |
Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ca | 2011 |
Abiraterone acetate in castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Androgen Antagonists; Androstadienes; Clinical Trials as Topic; Docetaxel; Huma | 2012 |
[Antisense oligonucleotide therapy for patients with castration-resistant prostate cancer].
Topics: Castration; Docetaxel; Humans; Male; Oligonucleotides, Antisense; Prednisolone; Prostatic Neoplasms; | 2011 |
[Toxic hepatitis and liver failure under therapy with flutamide].
Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Hormonal; Biopsy, Needle; Chemical and Drug I | 2004 |
Satraplatin in the treatment of hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; | 2005 |
The changing pattern of management for hormone-refractory, metastatic prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol | 2006 |
A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Res | 2006 |
[Primary non-Hodgkin lymphoma of the prostate: a case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyclophosphamide; Dau | 1993 |
Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: a decade of progress?
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 2000 |
[Chemotherapy of prostatic cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; | 1985 |
21 trials available for prednisolone and Cancer of Prostate
| Article | Year |
|---|---|
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).
Topics: Abiraterone Acetate; Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Fol | 2022 |
Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data.
Topics: Abiraterone Acetate; Acetates; Androgen Antagonists; Cost-Benefit Analysis; Hormones; Humans; Male; | 2022 |
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.
Topics: Abiraterone Acetate; Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols | 2023 |
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C | 2017 |
Gemcitabine-oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Ch | 2014 |
A randomized phase II trial comparing weekly taxotere plus prednisolone versus prednisolone alone in androgen-independent prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dise | 2008 |
Oral vinorelbine as first line chemotherapy in unfit elderly patients with hormone-refractory prostate cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Com | 2008 |
A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Surviva | 2009 |
[Combined treatment of metastatic hormone-resistant prostate cancer].
Topics: Aged; Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chem | 2009 |
Docetaxel-prednisolone combination therapy for Japanese patients with hormone-refractory prostate cancer: a single institution experience.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxe | 2010 |
Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Docetaxel | 2010 |
Prolonged treatment with three-weekly docetaxel plus daily prednisolone for metastatic castration-resistant prostate cancer: a multicenter, phase II, open-label, non-comparative, extension study in Japan.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Drug- | 2013 |
Efficacy of taxotere, thalidomide, and prednisolone in patients with hormone-resistant metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease-Fre | 2012 |
Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Mi | 2007 |
Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter Phase II trial in Japan.
Topics: Aged; Alopecia; Anorexia; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Prot | 2008 |
Chemotherapy in metastatic, hormone refractory prostatic cancer using chlorambucil in combination with prednisolone versus conjugate, prednimustine (Leo 1031).
Topics: Aged; Antineoplastic Agents; Chlorambucil; Clinical Trials as Topic; Drug Therapy, Combination; Huma | 1981 |
Is prednisolone as good as flutamide in hormone refractory metastatic carcinoma of the prostate?
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Humans; M | 1997 |
Antiemetic efficacy of prednisolone: a placebo-controlled trial in patients with advanced prostatic cancer treated with estramustine phosphate.
Topics: Aged; Antiemetics; Antineoplastic Agents, Alkylating; Area Under Curve; Double-Blind Method; Estramu | 1998 |
[Clinical evaluation of low dose glucocorticoid therapy for hormone-refractory prostate cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Dexamethasone; Drug Adm | 2000 |
[Chemotherapy of advanced prostate cancer].
Topics: Chlorambucil; Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; Diethylstilbestrol; Drug Eval | 1977 |
60 other studies available for prednisolone and Cancer of Prostate
| Article | Year |
|---|---|
Synthesis and biological analysis of prostate-specific membrane antigen-targeted anticancer prodrugs.
Topics: Antigens, Surface; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Screening Assays, An | 2010 |
Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high-risk metastatic hormone-sensitive prostate cancer.
Topics: Abiraterone Acetate; Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; | 2022 |
Re: Abiraterone Acetate and Prednisolone With or Without Enzalutamide for High-risk Non-metastatic Prostate Cancer: A Meta-analysis of Primary Results from Two Randomized Controlled Phase 3 Trials of the STAMPEDE Platform Protocol.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials, Ph | 2022 |
The Swedish national guidelines on prostate cancer, part 1: early detection, diagnostics, staging, patient support and primary management of non-metastatic disease.
Topics: Gonadotropin-Releasing Hormone; Humans; Iodine; Male; Neoplasm Staging; Povidone; Prednisolone; Pros | 2022 |
Comparison of Weekly Low Dose Docetaxel with the Standard Protocol in Hormone-resistant Metastatic Prostate Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Hormones; Humans; Male; Prednisolon | 2022 |
Treatment strategies and outcomes in a long-term registry study of patients with high-risk metastatic hormone-naïve prostate cancer in Japan: An interim analysis of the J-ROCK study.
Topics: Abiraterone Acetate; Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols | 2022 |
Treatment options for patients with prostate cancer who develop metastatic disease after hormonal therapy.
Topics: Abiraterone Acetate; Absorptiometry, Photon; Aged; Antineoplastic Combined Chemotherapy Protocols; B | 2019 |
Considering bone health in the treatment of prostate cancer bone metastasis based on the results of the ERA-223 trial.
Topics: Abiraterone Acetate; Bone Density; Bone Neoplasms; Double-Blind Method; Humans; Male; Prednisolone; | 2019 |
Bacterial steroid-17,20-desmolase is a taxonomically rare enzymatic pathway that converts prednisone to 1,4-androstanediene-3,11,17-trione, a metabolite that causes proliferation of prostate cancer cells.
Topics: Adrenal Glands; Androgens; Androstadienes; Cell Line, Tumor; Cell Proliferation; Clostridiales; Gluc | 2020 |
[Comparison of Abiraterone Acetate Plus Prednisolone and Combined Androgen Blockade in High-risk Metastatic Hormone-Sensitive Prostate Cancer].
Topics: Abiraterone Acetate; Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols | 2020 |
Commentary on: Abiraterone Plus Prednisolone in Metastatic, Castration-sensitive Prostate Cancer.
Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Castration; Diseas | 2017 |
Real-world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemot | 2018 |
Appendix 1: Cancer of the Prostate: eUpdate published online 28 September 2017 (http://www.esmo.org/Guidelines/Genitourinary-Cancers/Cancer-of-the-Prostate).
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemothe | 2018 |
Combination therapies in prostate cancer: proceed with caution.
Topics: Abiraterone Acetate; Double-Blind Method; Humans; Male; Prednisolone; Prednisone; Prostatic Neoplasm | 2019 |
Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100).
Topics: Aged; Aged, 80 and over; Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined C | 2013 |
Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.
Topics: Androstenols; Humans; Male; Phenylthiohydantoin; Prednisolone; Prostatic Neoplasms; Receptors, Andro | 2013 |
[Successful treatment with docetaxel and prednisolone for paxlitaxel and carboplatin-resistant prostate cancer].
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineopl | 2013 |
[A case on hemodialysis with castration-resistant prostate cancer which responded to combination chemotherapy with docetaxel and prednisolone].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Castration; Docetaxel; Humans; Kidney Failure, | 2013 |
Cutaneous metastasis of prostate carcinoma treated with radiotherapy: a case presentation.
Topics: Aged; Humans; Male; Mitoxantrone; Prednisolone; Prostatic Neoplasms; Skin Neoplasms | 2014 |
Translating Clinical Evidence-Based Medicine into the Real World: Single-Center Experience with Cabazitaxel in Metastatic Prostate Cancer Patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Evidence-Based Med | 2016 |
Unusual co-occurrence of Evans syndrome and pure red cell aplasia in elderly patient with prostate cancer.
Topics: Adenocarcinoma; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Humans; Male; Paraneoplastic Syndr | 2016 |
Dexamethasone did not suppress immune boosting by personalized peptide vaccination for advanced prostate cancer patients.
Topics: Aged; Antibody Formation; Antineoplastic Agents, Hormonal; Cancer Vaccines; Combined Modality Therap | 2008 |
Docetaxel in combination with prednisolone for hormone refractory prostate cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Respons | 2010 |
Temporary improvement in activities of daily living after steroid therapy for the treatment of anti-Hu antibody-associated syndrome in a patient with advanced prostate cancer.
Topics: Activities of Daily Living; Adenocarcinoma; ELAV Proteins; Glucocorticoids; Humans; Male; Middle Age | 2011 |
[A case of castration-refractory prostate cancer showing marked decrease of serum PSA level after zoledronic acid treatment with estramustine phosphate and prednisolone].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Castration; Diphosphonates; Es | 2011 |
Interstitial pneumonitis induced by bicalutamide given for prostate cancer.
Topics: Aged; Androgen Antagonists; Anilides; Bone Neoplasms; Castration; Humans; Lung Diseases, Interstitia | 2011 |
[A case of prednisolone therapy for radiation-induced hemorrhagic cystitis].
Topics: Administration, Oral; Aged; Cystitis; Glucocorticoids; Hemorrhage; Humans; Male; Prednisolone; Prost | 2011 |
5α-reductase inhibitors, antiviral and anti-tumor activities of some steroidal cyanopyridinone derivatives.
Topics: 5-alpha Reductase Inhibitors; Animals; Antineoplastic Agents; Antiviral Agents; Cell Line, Tumor; Ch | 2012 |
Primary cutaneous nocardiosis caused by Nocardia beijingensis in an immunocompromised patient with chemotherapy for advanced prostate cancer.
Topics: Aged; Anti-Bacterial Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2012 |
Cerebellar axial postural tremor complicating radiotherapy for prostate cancer.
Topics: Aged; Cerebellar Ataxia; Glucocorticoids; Humans; Male; Posture; Prednisolone; Prostatic Neoplasms; | 2012 |
Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.
Topics: Androgen Receptor Antagonists; Androgens; Androstenes; Androstenols; Anilides; Benzamides; Binding, | 2012 |
Cabazitaxel rechallenge at prostate-specific antigen relapse after previous cabazitaxel and docetaxel chemotherapy: case report.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Drug R | 2012 |
[Cabazitaxel after docetaxel: a new option in metastatic castration-resistant prostate cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Doc | 2012 |
NICE guidance on abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen.
Topics: Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Pro | 2012 |
[A case of dermatomyositis associated with prostatic carcinoma: a case report].
Topics: Adenocarcinoma; Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Hormonal; Dermatomyositis; Di | 2004 |
A modified low-dose regimen of mitoxantrone and prednisolone in patients with androgen-independent prostate cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Administrati | 2004 |
Interstitial pneumonitis related to flutamide monotherapy for prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Flutamide; Humans; Lung Di | 2004 |
[Therapy of painful bone metastases in patients with prostate carcinoma. The AP 32/02 Study of the AUO].
Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Humans; Ibandronic Acid; Male; Mitoxantrone; | 2004 |
Fulminant liver failure caused by cyproterone.
Topics: Aged; Alanine Transaminase; Androgen Antagonists; Cyproterone; Gastrointestinal Agents; Glutamyl Ami | 2005 |
Prolonging survival in prostate cancer: chemotherapy will have an important role.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Ne | 2005 |
[A case of malignant lymphoma of the prostate].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; D | 2005 |
Docetaxel-based regimens, the standard of care for metastatic androgen-insensitive prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Docetaxel; Huma | 2005 |
[Adenocarcinoma of the prostate associated with anti Jo-1 antibody positive polymyositis].
Topics: Adenocarcinoma; Aged; Anti-Inflammatory Agents; Antibodies, Antinuclear; Humans; Magnetic Resonance | 2006 |
[A case of hormone-refractory prostate cancer (HRPC) with tumor fever responding to docetaxel plus prednisolone therapy].
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2006 |
Editorial comment on: Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prednisolone; Prostatic Neo | 2007 |
The preliminary results of docetaxel-prednisolone combination therapy for the Japanese patients with hormone-refractory prostate cancer.
Topics: Administration, Oral; Aged; Ambulatory Care; Docetaxel; Drug Administration Schedule; Drug Therapy, | 2007 |
American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 3.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2007 |
Cyclophosphamide-prednisolone therapy in advanced prostatic carcinoma.
Topics: Acid Phosphatase; Cyclophosphamide; Drug Therapy, Combination; Humans; Male; Neoplasm Metastasis; Pr | 1980 |
[Malignant lymphoma of the prostate--a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphom | 1993 |
[Secondary non-Hodgkin lymphoma of the prostate: a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphom | 1996 |
[A case of hormone-refractory prostate cancer responsive to low-dose prednisolone therapy].
Topics: Aged; Antineoplastic Agents, Hormonal; Glucocorticoids; Humans; Male; Prednisolone; Prostate-Specifi | 1997 |
The use of estramustine and prednimustine versus prednimustine alone in advanced metastatic prostatic cancer patients who have received prior irradiation.
Topics: Chlorambucil; Drug Therapy, Combination; Estramustine; Humans; Male; Nausea; Neoplasm Metastasis; Ni | 1979 |
Prednimustine therapy for advanced prostatic cancer.
Topics: Adrenal Glands; Aged; Chemical Phenomena; Chemistry; Chlorambucil; Drug Combinations; Humans; Male; | 1978 |
Clinical experience with estramustine phosphate and predinimustine, two steroidal alkylating agents compounds [proceedings].
Topics: Chlorambucil; Estramustine; Humans; Male; Nitrogen Mustard Compounds; Prednisolone; Prostatic Neopla | 1978 |
Combined therapy of advanced prostatic carcinoma with estramustine and prednimustine.
Topics: Aged; Antineoplastic Agents; Chlorambucil; Drug Therapy, Combination; Estramustine; Humans; Male; Mi | 1977 |
Non-specific granulomatous prostatitis treated with steroids.
Topics: Aged; Biopsy, Needle; Diagnosis, Differential; Drug Administration Schedule; Granuloma; Humans; Male | 1991 |
Weekly low-dose adriamycin in hormone-resistant metastatic cancer of the prostate.
Topics: Aged; Bone Neoplasms; Doxorubicin; Drug Resistance; Estradiol Congeners; Humans; Infusions, Intraven | 1987 |
[Triple malignancy including bladder carcinoma, prostate carcinoma and malignant lymphoma: a case report].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; | 1989 |
High-dose medroxyprogesterone acetate versus prednisolone in hormone-resistant prostatic cancer. A pilot study.
Topics: Acid Phosphatase; Aged; Antineoplastic Agents; Humans; Male; Medroxyprogesterone; Medroxyprogesteron | 1985 |
Applications of the dermo-jet in urology.
Topics: Animals; Cicatrix; Cystoscopes; Dogs; Female; Glucocorticoids; Humans; Injections; Male; Methods; Me | 1970 |